Adriana Buskin,Lili Zhu,Valeria Chichagova,Basudha Basu,Sina Mozaffari-Jovin,David Dolan,Alastair Droop,Joseph Collin,Revital Bronstein,Sudeep Mehrotra,Michael Farkas,Gerrit Hilgen,Kathryn White,Dean Hallam,Katarzyna Bialas,Git Chung,Carla Mellough,Yuchun Ding,Natalio Krasnogor,Stefan Przyborski,Jumana Al-Aama,Sameer Alharthi,Yaobo Xu,Gabrielle Wheway,Katarzyna Szymanska,Martin McKibbin,Chris F Inglehearn,David J Elliott,Susan Lindsay,Robin R Ali,David H Steel,Lyle Armstrong,Evelyne Sernagor,Eric Pierce,Reinhard Lüehrmann,Sushma-Nagaraja Grellscheid,Colin A Johnson,Majlinda Lako

Abstract:Summary Mutations in pre-mRNA processing factors (PRPFs) cause 40% of autosomal dominant retinitis pigmentosa (RP), but it is unclear why mutations in ubiquitously expressed PRPFs cause retinal disease. To understand the molecular basis of this phenotype, we have generated RP type 11 (PRPF31- mutated) patient-specific retinal organoids and retinal pigment epithelium (RPE) from induced pluripotent stem cells (iPSC). Impaired alternative splicing of genes encoding pre-mRNA splicing proteins occurred in patient-specific retinal cells and Prpf31 +/− mouse retinae, but not fibroblasts and iPSCs, providing mechanistic insights into retinal-specific phenotypes of PRPFs. RPE was the most affected, characterised by loss of apical-basal polarity, reduced trans-epithelial resistance, phagocytic capacity, microvilli, and cilia length and incidence. Disrupted cilia morphology was observed in patient-derived-photoreceptors that displayed progressive features associated with degeneration and cell stress. In situ gene-editing of a pathogenic mutation rescued key structural and functional phenotypes in RPE and photoreceptors, providing proof-of-concept for future therapeutic strategies. eTOC PRPF31 is a ubiquitously expressed pre-mRNA processing factor that when mutated causes autosomal dominant RP. Using a patient-specific iPSC approach, Buskin and Zhu et al. show that retinal-specific defects result from altered splicing of genes involved in the splicing process itself, leading to impaired splicing, loss of RPE polarity and diminished phagocytic ability as well as reduced cilia incidence and length in both photoreceptors and RPE. Highlights Successful generation of iPSC-derived RPE and photoreceptors from four RP type 11 patients RPE cells express the mutant PRPF31 protein and show the lowest expression of wildtype protein PRPF31 mutations result in altered splicing of genes involved in pre-mRNA splicing in RPE and retinal organoids Prpf31 haploinsufficiency results in altered splicing of genes involved in pre-mRNA splicing in mouse retina RPE cells display loss of polarity, reduced barrier function and phagocytosis Photoreceptors display shorter and fewer cilia and degenerative features RPE cells display most abnormalities suggesting they might be the primary site of pathogenesis In situ gene editing corrects the mutation and rescues key phenotypes

CRISPRi-Mediated Treatment of Dominant Rhodopsin-Associated Retinitis Pigmentosa

CRISPR/SaCas9-based gene editing rescues photoreceptor degeneration throughout a rhodopsin-associated autosomal dominant retinitis pigmentosa mouse model

Treatment of autosomal dominant retinitis pigmentosa caused by RHO-P23H mutation with high-fidelity Cas13X in mice

Knockout and replacement gene surgery to treat rhodopsin-mediated autosomal dominant retinitis pigmentosa.

Allele-Specific Knockout by CRISPR/Cas to Treat Autosomal Dominant Retinitis Pigmentosa Caused by the G56R Mutation in NR2E3

In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa

Restoration of RPGR expression in vivo using CRISPR/Cas9 gene editing

In Vivo CRISPR/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in a Mouse Model of X-Linked Retinitis Pigmentosa

Disease modeling and pharmacological rescue of autosomal dominant retinitis pigmentosa associated with RHO copy number variation

CRISPR DNA Base Editing Strategies for Treating Retinitis Pigmentosa Caused by Mutations in Rhodopsin

AAV-mediated ERdj5 overexpression protects against P23H rhodopsin toxicity

Proinflammatory Pathways Are Activated in the Human Q344X Rhodopsin Knock-In Mouse Model of Retinitis Pigmentosa

Cellular expression and siRNA-mediated interference of rhodopsin cis-acting splicing mutants associated with autosomal dominant retinitis pigmentosa

A Precision Therapy Approach for Retinitis Pigmentosa 11 Using Splice-Switching Antisense Oligonucleotides to Restore the Open Reading Frame of PRPF31

Potential of Small Molecule-Mediated Reprogramming of Rod Photoreceptors to Treat Retinitis Pigmentosa

Rhodopsin-associated retinal dystrophy: Disease mechanisms and therapeutic strategies

CRISPR editing of anti-anemia drug target rescues independent preclinical models of retinitis pigmentosa

Human iPSC-derived RPE and retinal organoids reveal impaired alternative splicing of genes involved in pre-mRNA splicing in PRPF31 autosomal dominant retinitis pigmentosa

Nonretinoid chaperones improve rhodopsin homeostasis in a mouse model of retinitis pigmentosa

CRISPR Interference–Potential Application in Retinal Disease

Gene Correction Recovers Phagocytosis in Retinal Pigment Epithelium Derived from Retinitis Pigmentosa-Human-Induced Pluripotent Stem Cells